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Background: Transforming growth factor β (TGF-β), retinoic acid (RA), p38 mitogen-activated protein kinase (MAPK), 
and MEK signaling play critical roles in cell differentiation, proliferation, and apoptosis. We investigated the effect of RA 
and the role of these signaling molecules on the phosphorylation of Smad2/3 (p-Smad2/3) induced by TGF-β1.
Methods: A549 epithelial cells and CCD-11Lu fibroblasts were incubated and stimulated with or without all-trans RA 
(ATRA) and TGF-β1 and with MAPK or MEK inhibitors. The levels of p-Smad2/3 were analyzed by western blotting. For 
animal models, we studied three experimental mouse groups: control, bleomycin, and bleomycin+ATRA group. Changes 
in histopathology, lung injury score, and levels of TGF-β1 and Smad3 were evaluated at 1 and 3 weeks.
Results: When A549 cells were pre-stimulated with TGF-β1 prior to RA treatment, RA completely inhibited the 
p-Smad2/3. However, when A549 cells were pre-treated with RA prior to TGF-β1 stimulation, RA did not completely 
suppress the p-Smad2/3. When A549 cells were pre-treated with MAPK inhibitor, TGF-β1 failed to phosphorylate 
Smad2/3. In fibroblasts, p38 MAPK inhibitor suppressed TGF-β1–induced p-Smad2. In a bleomycin-induced lung injury 
mouse model, RA decreased the expression of TGF-β1 and Smad3 at 1 and 3 weeks.
Conclusion: RA had inhibitory effects on the phosphorylation of Smad induced by TGF-β1 in vitro , and RA also 
decreased the expression of TGF-β1 at 1 and 3 weeks in vivo. Furthermore, pre-treatment with a MAPK inhibitor showed 
a preventative effect on TGF-β1/Smad phosphorylation in epithelial cells. As a result, a combination of RA and MAPK 
inhibitors may suppress the TGF-β1–induced lung injury and fibrosis.
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Introduction
Abnormal wound healing in pulmonary fibrosis is charac-
terized by fibroblast and myofibroblast migration and prolif-
eration, decreased myofibroblast apoptosis, and increased 
activity of and responses to fibrogenic cytokines, especially 
transforming growth factor β1 (TGF-β1)1-3. 
TGF-β induces phosphorylation of Smad2/3, which is re-
leased and further propagates the signal of TGF-β. Changes 
in the level of Smad have been reported in human fibroblasts 
and epithelial cells following treatment with glucocorticoids, 
interferon-γ, and pirfenidone4-6. TGF-β1 utilizes not only the 
Smad pathway, but also non-Smad pathways. These non-
Smad pathways include the following signaling pathways 
and molecules: the phosphatidylinositol-3-kinase (PI3K)/
Akt pathways, mitogen-activated protein kinase (MAPK), and 
Rho-like GTPase7. Pendaries et al.8 reported that retinoic acid 
receptors (RARs) interfere with the TGF-β signaling pathway.
Retinoic acids (RAs), which are active vitamin A derivatives, 
play a critical role in cell differentiation, proliferation, and 
apoptosis8-10. It has been established that RA exerts its action 
through the activation of RARs and retinoid X receptors that 
regulate various transcriptional factors11. Understanding the 
roles of RA can provide new insights into the products of on-
cogenes/suppressor genes and the chronic fibrosis of human 
organs as it is associated with the TGF-β1 signaling pathway. 
Additionally, it is well-known that TGF-β1 activates the 
extracellular-signal-regulated kinase and the MAPK pathway 
through mitogen-activated protein/extracellular signal-regu-
lated kinase (MEK) in the non-Smad pathway7.
The purpose of this investigation was to determine whether 
RAs could inhibit the TGF-β1 induced phosphorylation of 
Smad2/3, and to determine the difference in TGF-β1 ex-
pression between epithelial cells and fibroblasts upon pre-
treatment with MAPK inhibitors. Additionally, we aimed to 
compare the degree of expression between phospho-Smad2 
(p-Smad2) and 3 (p-Smad3) in each cell type. Furthermore, 
we intended to confirm the effect of TGF-β1 and RA in a bleo-
mycin-induced lung injury and fibrosis mouse model.
Materials and Methods
1. Human epithelial cell line and fibroblast cell line 
The A549 epithelial and CCD-11Lu fibroblast cell lines that 
were used for the experiments in this study were purchased 
from the American Type Culture Collection (ATCC, Rockville, 
MD, USA). 
The study design in this report was approved by the Institu-
tional Animal Care Committee at the Medical College of Yon-
sei University (2014-0368). This experiment was performed in 
compliance with recommendations in the Guide for the Care 
and Use of Laboratory Animals by the National Institutes of 
Health.
2. Chemicals and antibodies 
TGF-β1 was purchased from Calbiochem (San Diego, CA, 
USA). Three types of RA, including all-trans  retinoic acid 
(ATRA), 9-cis RA, and 13-cis RA were purchased from Sigma-
Aldrich (St. Louis, MO, USA). The primary antibodies to Smad 
proteins for use in western blotting were obtained from Cell 
Signaling Technology (Danvers, MA, USA) and Zymed (San 
Francisco, CA, USA). β-Actin was used as a negative control, 
and was obtained from Delta Biolabs (Gilroy, CA, USA). The 
MEK 1/2 inhibitor, U0126, was purchased from Cell Signaling 
Technology (Beverly, MA, USA) and the p38 MAPK inhibitor 
(SB203580) was purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA).
3. Cell culture and chemical stimulation 
A549 cells were cultured in RPMI 1640 medium (Gibco 
BRL, Grand Island, NY, USA) supplemented with 10% fetal bo-
vine serum (FBS; Gibco BRL). CCD-11Lu cells were cultured 
in EMEM (Beckton Dickinson & Company, Lincoln Park, NJ, 
USA). Cells were incubated at 37°C with 5% CO2 for 24-hour 
durations, and subcultured two-to-three times, weekly, to 
maintain log phase growth.
To examine the effects of RA on the phosphorylation of 
Smad induced by TGF-β1, A549 cells were stimulated as 
follows: (1) TGF-β1, (2) RA, (3) 1 hour pre-stimulated with 
TGF-β1 prior to RA treatment, and (4) 1 hour pre-treated with 
RA prior to TGF-β1 stimulation. As a negative control, cells 
were incubated with only culture medium.
In total, 10-6 mol/L of each individual RA and/or 5 ng/mL of 
TGF-β1 were administered to the cells. RA and TGF-β1 were 
administered to A549 cells without delay. After stimulation, 
A549 cells were incubated for 24 hours, and then subjected to 
western blotting, as described below. 
In a separate experiment, to investigate the effects of 
TGF-β1 on A549 cells and CCD-11Lu cells, each cell line was 
pre-treated with a p38 MAPK inhibitor, a MEK 1/2 inhibitor, or 
neither (control). These pre-treated cells were stimulated as 
described above; (1) TGF-β1, (2) RA, (3) pre-stimulated with 
TGF-β1 prior to RA treatment, and (4) pre-treated with RA 
prior to TGF-β1 stimulation. 
4. Western blotting analysis (in vitro)
2×106 cells were dissolved in 100-mm culture plates and 
pre-incubated with RPMI 1640 medium. After 24 hours in the 
presence or absence of chemical stimulation, as described 
above, cells were washed twice with cold phosphate buffered 
saline (PBS), scraped and solubilized in a RIPA-B buffer con-
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taining 0.5% nonidet P-40, 20 mM Tris-HCl (pH 8.0), 50 mM 
NaCl, 50 mM NaF, 100 μM Na3VO4, 1 mM DTT, 50 μg/mL 
phenylmethanesulfonylfluoride, 20 μg/mL aprotinin, and 20 
μg/mL leupeptin. After 30 minutes at 4°C, cell lysates were 
cleared of debris by centrifugation at 12,000 rpm at 4°C for 
20 minutes. The protein lysates (20 μg) were applied to 10% 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
gel (SDS-PAGE) gels and transferred to nitrocellulose mem-
branes (Amersham Biosciences, Piscataway, NJ, USA). The 
membranes were blocked at room temperature with 5% skim 
milk in TBST (1×TBS, 0.1% Tween 20). After washing twice 
in TBST, the membranes were incubated with primary Smad 
antibodies for 2 hours at room temperature. The membranes 
were then washed 3 times for 10 minutes, each, in TBST, and 
incubated with the relevant horseradish peroxidase–conju-
gated secondary antibodies (diluted 1:1,000 in 3% bovine se-
rum albumin in TBST) for 1 hour. After washing three times in 
TBST, the reactive proteins were visualized using an enhanced 
chemiluminescence detection system (Amersham Biosci-
ences). 
5. Bleomycin-induced lung injury and fibrosis model
Male C57BL/6J mice, 7 weeks old and weighing 18–22 g, 
were purchased from Orient Bio (Seongnam, Korea). Mice 
were provided with rodent food and water in a controlled 
environment. Twelve mice were divided into the following 
three groups (n=4/group): (A) a control group with PBS inha-
lation, (B) a bleomycin plus PBS group, and (C) a bleomycin 
plus ATRA (25 mg/kg) group. Bleomycin (3 mg/mL; Dong-A 
Pharmaceutical, Co., Ltd., Seoul, Korea) was dissolved in PBS 
(3 mL). The mice were first lightly anesthetized by inhalation 
of isoflurane (Abbott Laboratories, North Chicago, IL, USA) in 
a supine position, and then PBS and bleomycin (50 μL) were 
administered intranasally. In the bleomycin plus ATRA group, 
0.5 mg of ATRA (Sigma) powder dissolved in 0.1 mL dimethyl 
sulfoxide (DMSO) was injected. In the bleomycin plus ATRA 
group, bleomycin was only once inhaled and ATRA was in-
jected three times per week, through intrapenitoneum. To col-
lect lung specimens, the experimental mice were sacrificed on 
day 7 or day 21 using a lethal overdose of xylazine.
 6. Histology
The pulmonary artery was flushed with sterile saline at 
low pressure, and the right lung was excised and stored at 
–80°C. Before the left lung was excised, it was inflated via tra-
cheotomy using 4% low-melting point agarose in PBS at 25 
cm H2O pressure until pleural margins became sharp. After 
the left lungs were excised, the mouse lung tissues were fixed 
overnight in 10% formaldehyde in PBS, and embedded in par-
affin. Serial sections (5-μm thick) were then stained with he-
matoxylin and eosin or with Masson’s Trichrome stain. Lung 
injury score was calculated under a light microscope by two 
qualified investigators blinded to samples according to the 
weighted scale guideline12. 
7. Western blotting analysis (in vivo)
Using PRO-PREP Extraction Solution (600 μL, Cat. #17081, 
iNtRON Biotechnology, Seongnam, Korea), the excised frozen 
right lungs (10 mg) were mechanically homogenized, lysed by 
incubation for 20–30 minutes in a freezer at –20°C, and then 
centrifuged at 13,000 ×g for 30 minutes at 4°C. Equal aliquots 
of protein were resolved on SDS-PAGE and transferred to ni-
trocellulose membranes. The membranes were probed with 
TGF-β1 (Calbiochem), Smad3 (Millipore Technologies, Bil-
lerica, MA, USA), and α-tubulin (Cell Signaling Technology), 
labeled with anti-rabbit or anti-goat IgG conjugated to horse-
radish peroxidase, and visualized using a Super-Signal West 
Pico Chemiluminescence Detection Kit (Pierce, Rockford, IL, 
USA). Band densities were measured by the Alpha Ease FC 
software version 4.1.0 (Innotech, San Leandro, CA, USA). Im-
ages were analyzed semi-quantitatively using NIH Image J.
8. Hydroxyproline assay
The amount of collagen in the left lung was measured using 
a hydroxyproline assay kit (Cell Biolabs, San Diego, CA, USA). 
Lung tissue was homogenized in 100 mL of distilled water, 
and hydrolyzed in 100 μL 12 N HCl for 3 hours at 120°C. The 
hydrolyzed samples were mixed with 5 mg of activated char-
coal, and centrifuged at 10,000×g for 5 minutes at 4°C. The 
absorbance of hydroxyproline content was determined at a 
wavelength of 540 nm, and absolute values were determined 
from a standard curve.
9. Statistical analysis
Continuous variables were compared by a Mann‒Whitney 
U test. An adjusted p-value of <0.05 was significant. SPSS ver-
sion 22.0 (IBM Corp., Armonk, NY, USA) was used for all sta-
tistical analyses. 
Results
1. TGF-β1 induced Smad2/3 phosphorylation
To understand the early molecular mechanism involved in 
the TGF-β1 induced phosphorylation of Smad, the phosphor-
ylation of Smad2/3 was examined using a phospho-specific 
antibody. TGF-β1 stimulation induced the phosphorylation of 
Smad2/3 in A549 cells. Time-course analysis revealed that the 
phosphorylation of Smad2/3 was detected 15 minutes after 
TGF-β1 stimulation and lasted for 24 hours. The phosphoryla-
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tion of Smad2/3 in A549 cells reached its peak at 1 hour fol-
lowing TGF-β1 stimulation (Figure 1). 
2. The effects of Smad phosphorylation by RA and 
TGF-β1 stimulation 
To examine the dose-dependent effects of RA on the activa-
tion of Smad, RAs were dissolved in DMSO (final concentra-
tion in culture medium was 0.1%) and the final concentrations 
of the RAs were 10-7, 10-6, and 10-5 mol/L. A549 cells were incu-
bated with FBS-free RPMI alone or in the presence of various 
concentrations of each RA for 48 hours. They were subjected 
to western blotting to identify Smad2/3. The optimal RA con-
centration was 10-6 mol/L (Figure 2). 
Following TGF-β1 stimulation, both Smad2/3 and p-
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Figure 3. (A) Representative results of Smad expression by western blot upon pre-stimulation with TGF-β1 followed by administration of 
each of the three RAs. A549 cells were left untreated (control) or stimulated with one of the following conditions: TGF-β1 alone, each of the 
three RAs alone, or pre-stimulated with TGF-β1 followed by administration of one of the three retinoic acids. They were incubated for 24 
hours and electrophoresed on a 10% SDS-PAGE gel. The levels of Smad2/3 and p-Smad2/3 were analyzed by western blot. TGF-β1 activated 
Smad2/3 and increased p-Smad2/3. In contrast, RA administration completely inhibited the phosphorylation of Smad2/3. This was simi-
larly observed under conditions of pre-stimulated and simultaneous TGF-β1 administration followed by treatment with the three RAs. (B) 
Representative results of Smad expression by western blot upon pre-treatment with RA followed by TGF-β1 stimulation. A549 cells were left 
untreated (control) or stimulated with one of the following conditions: TGF-β1 alone, each of the three RAs alone or pre-treatment with each 
of the RAs followed administration of TGF-β1. The cells were incubated for 24 hours and electrophoresed on a 10% SDS-PAGE gel. The levels 
of Smad2/3 and p-Smad2/3 were analyzed by western blot. TGF-β1 activated Smad2/3 and increased p-Smad2/3. RA treatment completely 
inhibited the phosphorylation of Smad2/3. However, when pre-treated RA was administered, followed by TGF-β1 stimulation, RAs did not 
suppress the phosphorylation of Smad2/3. TGF-β1: transforming growth factor β1; ATRA: all-trans retinoic acid; RA: retinoic acid; SDS-PAGE: 
sodium dodecyl sulfate polyacrylamide gel electrophoresis gel.
Smad 2
Smad 3
-Actin
13-cis RA (mol/L)
Control 10
7
10
6
10
5
Smad 2
Smad 3
-Actin
9-cis RA (mol/L)
Control 10
7
10
6
10
5
Smad 2
Smad 3
-Actin
ATRA (mol/L)
Control 10
7
10
6
10
5
A B C
Figure 2. Representative results of Smad expression by western blot according to concentration of ATRA (A), 9-cis RA (B), and 13-cis RA (C) 
stimulation. After stimulation with various concentrations of the three RAs, A549 cells were incubated for 24 hours and then electrophoresed 
on a 10% SDS-PAGE gel. Expression of Smad2 and Smad3 protein was analyzed by western blot. The optimal concentration of the RAs was 
10-6 mol/L, stimulating the maximum expression of Smad2 and Smad3. ATRA: all-trans retinoic acid; RA: retinoic acid; SDS-PAGE: sodium 
dodecyl sulfate polyacrylamide gel electrophoresis gel.
Figure 1. Time-dependent phosphorylation of Smad2/3 induced 
by TGF-β1 5 ng/mL. After stimulation with 5 ng/mL TGF-β1, A549 
cells were incubated for the indicated times, and the reactive pro-
teins were electrophoresed on a 10% SDS-PAGE gel. The protein 
levels of Smad2/3 and p-Smad2/3 were analyzed by western blot. 
The phosphorylation of Smad2/3 reached a peak 1 hour following 
TGF-β1 stimulation. TGF-β1: transforming growth factor β1; SDS-
PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis 
gel.
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Smad2/3 were increased compared with the control A549 
cells. Each of the three RAs (10-6 mol/L), ATRA, 9-cis  RA, 
and 13-cis  RA, elicited a similar effect on Smad phosphory-
lation. The RAs selectively inhibited the phosphorylation 
of Smad2/3. When cells were pre-stimulated with TGF-β1 
and then treated with the three RAs, the phosphorylation of 
Smad2/3 was completely abrogated (Figure 3A). 
However, when the cells were stimulated with each of the 
RAs before TGF-β1, different results were observed. After 
stimulation with TGF-β1, the RAs completely inhibited the 
phosphorylation of Smad2/3, but when the cells were pre-
treated with RA and then stimulated with TGF-β1, the phos-
phorylation of Smad2/3 was not completely suppressed (Fig-
ure 3B).
3. Effects of ATRA and MAPK inhibitors differ between 
A549 epithelial cells and CCD-11Lu fibroblasts 
Similar to the A549 epithelial cells, TGF-β1 significantly in-
creased p-Smad2/3 expression in CCD-11Lu fibroblasts, and 
this effect was completely suppressed by administration of the 
ATRA. However, when these cells were pre-treated with each 
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Figure 4. (A‒C) Representative western blot results of A549 epithelial cell Smad expression upon pre-treatment with a p38 MAPK inhibitor 
(B) or a MEK inhibitor (C).  A549 cells were pre-treated with a p38 MAPK inhibitor or a MEK inhibitor, and then the cells were stimulated 
as follows: (1) control, (2) TGF-β1, (3) RA (ATRA), (4) pre-treated with RA (ATRA) prior to TGF-β1 stimulation, or (5) pre-stimulated with 
TGF-β1 prior to RA (ATRA) treatment. The cells were then incubated for 24 hours and electrophoresed on a 10% SDS-PAGE gel. The levels of 
Smad2/3 and p-Smad2/3 expression were analyzed by western blot. TGF-β1 did not significantly elevate p-Smad2 expression when epithelial 
cells were pre-treated with the p38 MAPK inhibitor. When epithelial cells were pre-treated with the MEK 1/2 inhibitor, p-Smad3 expression 
was not significantly increased by TGF-β1. MAPK: mitogen-activated protein kinase; TGF-β1: transforming growth factor β1; RA: retinoic 
acid; ATRA: all-trans retinoic acid; SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis gel. *p<0.05, **p<0.01, ***p<0.001.
Effect of retinoic acid and MAPK inhibitors
https://doi.org/10.4046/trd.2017.0111 47www.e-trd.org
of the ATRA, followed by TGF-β1 administration, suppression 
of p-Smad2/3 expression was not observed (Figures 4A, 5A).
To compare the effects of ATRA and MAPK inhibitors on 
the phosphorylation of Smad2/3 induced by TGF-β1 between 
A549 epithelial cells and CCD-11Lu fibroblasts, the cell lines 
were pre-treated with a p38 MAPK inhibitor (SB203580; 6 
μM for 30 minutes) or a MEK 1/2 inhibitor (U0126; 10 μM 
for 30 minutes) prior to administration of RA and/or TGF-β1 
(Figures 4B, C, 5B, C). TGF-β1 administration increased p-
Smad2/3 levels, both in A549 and CCD-11Lu cells. However, 
there were some differences between A549 and CCD-11Lu 
cells when they were pre-treated with the p38 MAPK inhibi-
tor. In A549 cells, TGF-β1 did not increase p-Smad2 levels. Ad-
ditionally, p-Smad2/3 levels in A549 cells pre-treated with the 
p38 MAPK inhibitor, followed by administration of TGF-β1, 
were lower than those in the cells that were not pre-treated. 
A549 cells pre-treated with the MEK 1/2 inhibitor showed 
stable p-Smad3 levels. Although TGF-β1 treatment elevated 
the levels of p-Smad2 significantly in A549 cells pre-treated 
with the MEK 1/2 inhibitor, p-Smad2 levels were lower than 
those in the cells that were not pre-treated.
In CCD-11Lu cells, regardless of pre-treatment with MAPK 
inhibitors, TGF-β1 increased p-Smad3 levels. p-Smad2 levels, 
however, were not increased in response to pre-treatment 
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Figure 5. (A‒C) Representative western blot results of CCD-11Lu fibroblast cell Smad expression upon pre-treatment with a p38 MAPK inhib-
itor (B) or a MEK inhibitor (C). CCD-11Lu cells were pre-treated with a p38 MAPK inhibitor or a MEK inhibitor, and then cells were stimulat-
ed as follows: (1) control, (2) TGF-β1, (3) RA (ATRA), (4) pre-treated with RA (ATRA) prior to TGF-β1 stimulation, or (5) pre-stimulated with 
TGF-β1 prior to RA (ATRA) treatment. CCD-11Lu cells were then incubated for 24 hours and electrophoresed on a 10% SDS-PAGE gel. The 
levels of Smad2/3 and p-Smad2/3 expression were analyzed by western blot. In fibroblasts pre-treated with the p38 MAPK inhibitor, TGF-β1 
did not significantly increase p-Smad2 expression. MAPK: mitogen-activated protein kinase; TGF-β1: transforming growth factor β1; RA: reti-
noic acid; ATRA: all-trans retinoic acid; SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis gel. **p<0.01, ***p<0.001.
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with the p38 MAPK inhibitor.
4. ATRA attenuates bleomycin-induced lung injury and 
fibrosis in mouse model
As shown in Figures 6 and 7, bleomycin treatment signifi-
cantly induced lung injury after both 1 week (p<0.05) and 3 
weeks (p<0.001), and ATRA significantly attenuated the lung 
injury at 3 weeks. At 1 week, the TGF-β and Smad3 levels in 
the bleomycin group were significantly increased compared 
with those in the control group (p<0.01 for both levels), but 
subsequent treatment with 0.5 mg ATRA significantly blocked 
this increase (p<0.001 for both levels) (Figure 8). However, at 
3 weeks, neither TGF-β nor Smad3 levels were significantly 
increased in the bleomycin group. ATRA only significantly 
blocked the increase of TGF-β levels (p<0.001), failing to sig-
nificantly block Smad3 levels (Figure 9). 
Discussion
In this study, we demonstrated that RA inhibits the phos-
phorylation of Smad2/3 induced by TGF-β1 in both epithelial 
cells and fibroblasts. In addition, the inhibition of Smad2/3 
phosphorylation using RA was clearly demonstrated in cells 
pre-treated with TGF-β1. This implies that RA may have an 
inhibitory effect on the progression of pulmonary fibrosis in 
patients who demonstrate activation and over-stimulation 
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Figure 6. Histological sections of lung fields stained with hematoxylin and eosin (A–F, ×400) and lung injury score (G, H) for the following 
treatments and at the specified timepoints: control at 1 week (A), bleomycin at 1 week (B), bleomycin followed by ATRA at 1 week (C), con-
trol at 3 weeks (D), bleomycin at 3 weeks (E), bleomycin followed by ATRA at 3 weeks (F), lung injury score at 1 week (G), and at 3 weeks (H). 
Bleomycin-induced lung damage and ATRA attenuates the lung injury. ATRA: all-trans retinoic acid; PBS: phosphate buffered saline; Bleo: 
bleomycin. *p<0.05, ***p<0.001.
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of TGF-β1, but not a preventative effect. This phenomenon 
was also investigated in a bleomycin-induced lung injury 
and fibrosis mouse model at 1 and 3 weeks. Furthermore, we 
demonstrated the inhibitory effect of pre-treatment with the 
p38 MAPK and MEK inhibitors on Smad phosphorylation 
induced by TGF-β1, and outlined differences in the effects on 
epithelial cells and fibroblasts. Our study suggests that a com-
bination of MAPK inhibitors and ATRA may exert preventa-
tive and inhibitory effects on pulmonary fibrosis.
There is evidence that interactions between RA and TGF-β 
play important roles in cellular proliferation and differentia-
tion, including modulation of the balance between these two 
processes13.
The effects of RA on pulmonary fibrosis have been inves-
tigated, and RA has been shown to inhibit TGF-β1–induced 
collagen production from human lung fibroblasts, as well as 
from both idiopathic pulmonary fibrosis and neonatal lung 
fibroblasts14,15. The inhibitory effects of RA on TGF-β1 are 
closely related to the phosphorylation of Smad316,17. A study 
demonstrated that ATRA prevents radiation- or bleomycin-
induced pulmonary fibrosis through reduced production of 
interleukin 6, TGF-β1, and collagen from human fetal lung 
fibroblasts18. These data may provide the rationale for explor-
ing the clinical use of ATRA for the prevention of radiation-
induced pulmonary fibrosis and other pathologic conditions 
involving pulmonary fibrosis. 
It has been shown that RA induced hypochondrogenesis 
through regulation of the TGF-β1 pathway, suggesting a role 
for TGF-β receptor II (TβRII)/Smad in retinoid-induced cleft 
palate19. In contrast to embryonic cells, RA increased8,20 or 
decreased21 expression of TGF-β1 in leukemic cells. TGF-β1 
in combination with ATRA acted synergistically to inhibit 
growth, and to stimulate apoptosis of these cells. The results 
for the effects of RA on the expression of TGF-β1 are con-
flicted; depending on cell type, culture conditions, and type of 
RA used, both elevations and reductions have been reported. 
This study demonstrated that RAs completely inhibited the 
phosphorylation of Smad2/3 in the presence of RA alone and 
when pre-stimulated with TGF-β1 followed by administra-
tion of RA. However, RAs did not completely suppress the 
phosphorylation of Smad2/3 when cells were pre-treated 
RA followed TGF-β1 stimulation. In our study, epithelial cells 
that were pre-treated with RA followed TGF-β1 stimulation 
showed greater phosphorylated Smad2/3 expression than 
TGF-β1 stimulated epithelial cells that were not pre-treated 
with RA. This might be the result of a different spatiotemporal 
status of pre-stimulation because cells pre-treated with RA 
have a higher responsiveness to TβRII induction to exogenous 
TGF-β1 administration, as was observed in HL-60 leukemic 
cells22, where the induction of TβRII led to an increased re-
sponse to exogenous TGF-β1 and increased phosphorylation 
of Smad2/3. 
In contrast, it might be the result of other mechanisms of 
Smad phosphorylation. TGF-β1 was shown to activate the 
PI3K and ERK pathways, which led to Smad3 phosphoryla-
tion at the linker region in rat myofibroblasts23. Additional 
studies are needed to elucidate the effects of RA on the various 
mechanisms of the TGF-β1 signal transduction pathway, and 
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Figure 7. Histological sections of lung fields stained with Masson’s trichrome stain and 
hydroxyproline content in lung tissue. (A) Control at 3 weeks (×400). (B) Bleomycin at 
3 weeks (×400). (C) Bleomycin followed by ATRA at 3 weeks (×400). (D) Hydroxypro-
line content in lung tissue at 3 weeks. Bleomycin-induced lung damage and ATRA at-
tenuates the lung injury. ATRA: all-trans retinoic acid; PBS, phosphate buffered saline; 
Bleo: bleomycin. **p<0.01, ***p<0.001.
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on the various target genes that promote fibrosis, apoptosis, 
and epithelial-mesenchymal transition (EMT).
Many studies have indicated that unregulated recovery 
of epithelial injury is the beginning and cause of pulmonary 
fibrosis pathogenesis1,24,25. Ross et al.26 demonstrated that 
Smad3 expression is regulated by mitogen-activated protein 
kinase kinase-1 (MEK1) in epithelial and smooth muscle cells. 
p-Smad3 was not increased in epithelial cells in our study 
upon pre-treatment with a MEK 1/2 inhibitor (Figure 4C). 
However, in fibroblasts pre-treated with the MEK 1/2 inhibitor, 
the effect of TGF-β1 was not inhibited (Figure 5C). Our study 
demonstrated that pre-treatment with MAPK inhibitors was 
effective in preventing the effect of TGF-β1 on epithelial cells. 
Through Smad or non-Smad pathway and extracellular 
stimuli, TGF-β activate all ERK, p38 MAPK, and JNK MAPK27. 
In our study, pre-treatment of epithelial cells and fibroblast 
with a p38 MAPK inhibitor showed a non-significant response 
to TGF-β1 in p-Smad2. Although TGF-β1 also significantly el-
evated p-Smad3 expression, regardless of pre-treatment with 
the p38 MAPK inhibitor, the levels of expression were lower in 
the absence of the inhibitor. Therefore, the p38 MAPK inhibi-
tor could be effective against both Smad2 and Smad3 phos-
phorylation.
Previous studies have demonstrated that TGF-β1 is associ-
ated with MAPK signaling and EMT induction28,29. Through 
EMT, epithelial cells might be converted to myofibroblasts30. 
Abnormal activated alveolar epithelial cells are important me-
diators that induce the formation of fibroblast and myofibro-
blast foci, which secrete excessive amounts of collagen, result-
ing in scarring and compromised lung function31. In our study, 
both fibroblasts and epithelial cells pre-treated with MAPK in-
hibitors showed significant decreases in Smad2 phosphoryla-
tion. Additionally, ATRA was shown to be effective in both epi-
thelial cells and fibroblasts, pre-treated with a MAPK inhibitor, 
in suppressing p-Smad3. Furthermore, bleomycin-induced 
lung injury and fibrosis was reduced in vivo by ATRA in our 
study. At 1 week, TGF-β and Smad3 levels were increased by 
bleomycin treatment and decreased by subsequent treatment 
with ATRA. At 3 weeks, TGF-β and Smad3 levels showed in-
creases similar to those shown at 1 week, but only the levels 
of TGF-β were significantly reduced by ATRA. This could be 
explained by the possibility that, while TGF-β and Smad3 
play important roles in bleomycin-induced lung damage at 1 
week, other pathways might exist in lung injury after 1 week. 
Shi et al.32 showed that the signal of TGF-β was significantly 
stronger than that in the control group in an animal model 
within 2 weeks, and the signal of TGF-β was weaker later, as 
observed in our results. Additional experiments are needed to 
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Figure 8. (A‒C) Expression of TGF-β and Smad3 in lung lysates 
upon treatment with bleomycin followed by ATRA, as measured 
by densitometry at 1 week for TGF-β (B) and Smad3 (C). Male 
C57BL/6J mice were stimulated as follows: (1) control, (2) bleomy-
cin, or (3) bleomycin followed by ATRA. Bleomycin significantly 
increased the levels of TGF-β and Smad3, and ATRA significantly 
decreased the levels of TGF-β and Smad3 at 1 week. TGF-β: trans-
forming growth factor β; ATRA: all-trans retinoic acid; PBS: phos-
phate buffered saline; Bleo: bleomycin. **p<0.01, ***p<0.001.
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Figure 9. (A‒C) Expression of TGF-β and Smad3 in lung lysates 
upon treatment with bleomycin followed by ATRA, as measured 
by densitometry at 3 weeks for TGF-β (B) and Smad3 (C). Male 
C57BL/6J mice were stimulated as follows: (1) control, (2) bleomy-
cin, or (3) bleomycin followed by ATRA. ATRA decreased the levels 
of TGF-β at 3 weeks but not of Smad3. TGF-β: transforming growth 
factor β; ATRA: all-trans retinoic acid; PBS: phosphate buffered sa-
line; Bleo: bleomycin. ***p<0.001.
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confirm the role of ATRA and MAPK inhibitors in bleomycin-
induced lung fibrosis according to time change. Therefore, 
early treatment with RA and MAPK inhibitors could be of use 
in preventing and inhibiting the effect of TGF-β1 in both epi-
thelial cells and fibroblasts. In addition, as shown in the mouse 
experiment, mechanisms of treatment other than ATRA are 
needed to lower the level of Smad.
In conclusion, our observations suggest that interactions 
between RA and TGF-β1 signal transduction pathways may, 
thus, provide a variety of mechanisms by which subtle altera-
tions in p-Smad expression. Administration of combinations 
of RA and MAPK inhibitors had inhibitory effects on the phos-
phorylation of Smad2/3 induced by TGF-β1.
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